Updated Results of the Selective Bruton Tyrosine kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies

Drug Category : Array
Conference Category : Array
Lead Author : Cheah C, et al.
Published Date : 18/06/2021
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2021/06/TG-1701-ICML21-Poster-Cheah-FINAL-PDF-6.18.21.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top